[AIDS and perinatal aspects]

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

[AIDS and perinatal aspects]

Bull Mem Acad R Med Belg. 1991;146(8-10):346-54; discussion 354-5. Unique Identifier : AIDSLINE MED/92274091
Henrion R; Clinique universitaire de Gynecologie-Obstetrique de; Port-Royal, Paris.

Abstract: The proportion of women among AIDS. patients in Europe is progressively rising. The male-to-female sex ratio had constantly decreased from 11.7% through 1984 (17 countries) to 5 in 1990 (31 countries). The proportion of female cases is greatest in Southern Europe, France and Belgium. This is related to the predominant transmission factors, homosexual in Northern Europe, IV drug use in Southern Europe and heterosexual in Belgium. In France, IV drug use predominates in the South, whereas heterosexual transmission is more frequent in the Paris area. Pregnancy does not appear to accelerate disease progression, except in women with symptomatic infection or low CD4 counts. Over 80% of infant AIDS cases are related to mother-to-child transmission. The rate of transmission is about 20%, higher in patients in advanced disease stages. A number of questions remain open. At what time in pregnancy, early gestation, late gestation and/or during labor, does transmission occur? Is the only mechanism of transmission transplacental, or can it also occur during delivery? Does placental transfer concern free virus, immune complexes and/or intracellular virus? Management of pregnancies with HIV infection concerns the entire European community. In France, pregnancy is discouraged among HIV-seropositive women. However, more than 1,500 do become pregnant each year. Testing is recommended at the first prenatal visit for all women, and repeated regularly for seronegative women with HIV-infected partners. Preconceptional testing should be proposed whenever possible. The decision whether to continue or to terminate pregnancy is a woman's choice. Complete information and counseling must take into account the patient's disease status.(ABSTRACT TRUNCATED AT 250 WORDS)

Keywords: Acquired Immunodeficiency Syndrome/CONGENITAL/THERAPY English Abstract Female Human HIV Infections/*THERAPY Infant, Newborn Infant, Newborn, Diseases/ETIOLOGY Maternal-Fetal Exchange Opportunistic Infections/COMPLICATIONS Pregnancy Pregnancy Complications, Infectious/*THERAPY Zidovudine/THERAPEUTIC USE JOURNAL ARTICLE
920930
M9290891

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .